List
Of
Controlled
Substances

For the
State
Of
Arkansas
Pursuant to the provisions of Arkansas Code Annotated § 5-64-201 and § 5-64-216 of the laws of the State of Arkansas, the Director of the Arkansas Department of Health or duly authorized agent, as specified by law, is giving public notice of the publication of the List of Controlled Substances for the State of Arkansas.

Due consideration has been given applicable federal regulations, current scientific knowledge regarding the listed substances, the evidence of actual or relative potential for abuse, the history and current patterns of abuse, the risk to the public health, and potential to produce psychic or psychological dependence liability.

Based on these considerations the attached listing of the Schedule of Controlled Substances and the corresponding drugs that are included in each schedule is hereby promulgated by the Director of the Arkansas Department of Health as the List of Controlled Substances for the State of Arkansas.

Each controlled substance or basic class thereof has been assigned an "Administration Controlled Substance Code Number" for purposes of identification. These numbers are for internal management and are used as a means to identify substances with complex and cumbersome chemical names.

Next to the code number is the date the substance was placed in schedule by the Director of the Arkansas Department of Health.

I, Shane David, Pharm.D., Section Chief of Pharmacy Services for the Arkansas Department of Health, do hereby certify that the documents attached hereto are true and correct copies of the current List of Controlled Substances adopted by the Arkansas State Board of Health in accordance with Arkansas state law.

Shane David, Pharm.D., Section Chief
Pharmacy Services Branch

STATE OF ARKANSAS

COUNTY OF SALINE

I, Marci Middleton, do hereby certify that Shane David, Pharm.D., well known to me, appeared before me and signed the above referenced document.

Sworn and subscribed to before me this day of , ___.

Notary Public

My commission expires

DRAFT 6/3/2019
ARKANSAS DEPARTMENT OF HEALTH

LIST OF CONTROLLED SUBSTANCES

SECTION I AUTHORITY

The following scheduling of these controlled substances has been hereby promulgated pursuant to Arkansas Stat. Ann. §5-64-201 and §5-64-216.

SECTION II PURPOSE

Due consideration has been given applicable Federal regulations, current scientific knowledge regarding the listed substances, the evidence of actual or relative potential for abuse, the history and current patterns of abuse, the risk to the public health, and potential to produce psychic or psychological dependence liability.

SECTION III GENERAL REQUIREMENTS

(Attached copy of the listing of scheduling of controlled substances)

SECTION IV REPEAL

All lists of schedules of controlled substances in conflict herewith are hereby repealed.

CERTIFICATION

This will certify the following list of scheduling of controlled substances was adopted by the Arkansas State Board of Health at a session of the Board held in Little Rock, Arkansas on the ___ day of ________, ________, and after a Public Hearing on the ___ day of ________, ________, held in Little Rock, Arkansas, at the State Department of Health Building.

__________________________
Nathaniel Smith, M.D., MPH
Director, Arkansas Department of Health

DRAFT 6/3/2019
ARTICLE II

Schedule I

(a) Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.

(b) Opiates: (Narcotic Drugs) Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, salts is possible within the specific chemical designation (for purposes of 3-methylthiofentanyl only, the term isomer includes the optical and geometric isomers):

<table>
<thead>
<tr>
<th>Code Number</th>
<th>Substance Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>9815-(2-86)</td>
<td>Acetyl-alpha-methylfentanyl (N-[1-[1-methyl-2-phenethyl]-4-piperidinyl]-N-phenylacetamide)</td>
</tr>
<tr>
<td>9601*</td>
<td>Acetylpropylendorphine</td>
</tr>
<tr>
<td>9602*</td>
<td>Allylbromadrol</td>
</tr>
<tr>
<td>9603*</td>
<td>Alphacetylmethadol (except Levo-alphacetylmethadol (LAAM))</td>
</tr>
<tr>
<td>9604*</td>
<td>Alphamethadone</td>
</tr>
<tr>
<td>9605*</td>
<td>Alphamethadol</td>
</tr>
<tr>
<td>9814-(6-82)</td>
<td>Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]propranololide; 1-(1-methyl-2-phenylethyl)-4(N-propanilido)piperidine)</td>
</tr>
<tr>
<td>9832-(2-86)</td>
<td>Alpha-methylthiofentanyl(N-[1-methyl-2-(2thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide)</td>
</tr>
<tr>
<td>9606*</td>
<td>Benzethidine</td>
</tr>
<tr>
<td>9607*</td>
<td>Betacetylmethadol</td>
</tr>
<tr>
<td>9830-(2-86)</td>
<td>Beta-hydroxyfentanyl(N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl][1-N-phenylpropanamide)</td>
</tr>
<tr>
<td>9831-(2-86)</td>
<td>Beta-hydroxy-3-methylfentanyl [other name: N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide]</td>
</tr>
<tr>
<td>9608*</td>
<td>Betamethadone</td>
</tr>
<tr>
<td>9609*</td>
<td>Betaprodine</td>
</tr>
<tr>
<td>9611*</td>
<td>Clonitazene</td>
</tr>
<tr>
<td>9612*</td>
<td>Dextromoramide</td>
</tr>
<tr>
<td>9613*</td>
<td>Diampromide</td>
</tr>
<tr>
<td>9615*</td>
<td>Diethylthiambutene</td>
</tr>
<tr>
<td>9616*</td>
<td>Difenoxtine</td>
</tr>
<tr>
<td>9618*</td>
<td>Dimenaxadol</td>
</tr>
<tr>
<td>9617*</td>
<td>Dimepethanol</td>
</tr>
<tr>
<td>9619*</td>
<td>Dimethylthiambutene</td>
</tr>
<tr>
<td>9621*</td>
<td>Dioxaphetyl butyrate</td>
</tr>
<tr>
<td>9622*</td>
<td>Dipipanone</td>
</tr>
<tr>
<td>9623*</td>
<td>Ethylmethyliambutene</td>
</tr>
<tr>
<td>9624*</td>
<td>Ethonitazene</td>
</tr>
<tr>
<td>9625*</td>
<td>Etoperidine</td>
</tr>
<tr>
<td>9627*</td>
<td>Furethidine</td>
</tr>
<tr>
<td>9628*</td>
<td>Ketobemidone</td>
</tr>
<tr>
<td>9629*</td>
<td>Levomoramide</td>
</tr>
<tr>
<td>9631*</td>
<td>Levophenacylmorphan</td>
</tr>
<tr>
<td>9813-(10-85)</td>
<td>3-Methylfentanyl (N-[3-Methyl-1-(2-phenylethyl)-4-piperidinyl]-N-phenylpropanamide)</td>
</tr>
</tbody>
</table>
(35) 3-methylthiofentanyl \(N-(3\text{-methyl-1-(2-thienyl)ethyl-4-piperidinyl})-N-\text{phenylpropanamide}\) 9833-(2-86)

(36) Morperidine 9632*

(37) MPPF \(1\text{-methyl-4-phenyl-4-propionoxypiperidine}\) 9661-(10-85)

(38) Noracemethadol 9633*

(39) Norlevorphanol 9634*

(40) Normethadone 9635*

(41) Norpipanone 9636*

(42) Para-fluorofentanyl \(N-(4\text{-fluorophenyl})-N-\text{[1-(2-phenethyl)-4-piperidinyl]}\text{propanamide}\) 9812-(11-86)

(43) PEPAF \(1\text{-[2-phenylethyl]-4-phenyl-4 acetyloxy)piperidine}\) 9663-(10-85)

(44) Phenadione 9637*

(45) Phenampromide 9638*

(46) Phenomorpham 9647*

(47) Phenoperidine 9641*

(48) Piriramamide 9642*

(49) Proheptazine 9643*

(50) Properidine 9644*

(51) Propiram 9649*

(52) Racemoramide 9645*

(53) Thiofentanyl \(N\text{-phenyl-N-\text{[1-(2-thienyl)ethyl-4-piperidinyl]}-propanamide}\) 9835-(2-86)

(54) Tildine 9750-(9-81)

(55) Trimperidine 9646*

(56) Acetyl fentanyl \(N-(\text{1-phenethylpiperidin-4-yl})-N-\text{phenylacetamide}\) 9821

(57) Butyryl fentanyl \(N-(\text{1-phenethylpiperidin-4-yl})-N-\text{phenylbutyramide}\) 9822

(58) Beta-hydroxythiofentanyl \(N-(\text{1-[2-hydroxy-2-(thiophen-2-yl)ethyl]}\text{piperidin-4-yl})-N-\text{phenylpropanamide}\) 9836

(59) Acetyl fentanyl 4-methylphenethyl analog \(N-(\text{-1-(2-4-methylphenyl)ethyl-4-piperidinyl})-\text{N-phenyl-acetamide monohydrochloride}\)

(60) Valeryl fentanyl \(N\text{-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]}\text{-pentanamide mono hydrochloride}\)

(61) Furanyl fentanyl \(N-(\text{-1-(2-phenylethyl)-4-piperidinyl})-\text{-N-phenylfuran-2-carboxamide}\) 9834

(62) Isobutyryl fentanyl \(2\text{-methyl-N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]}\text{-propanamide mono hydrochloride}\)

(63) Ofcfentanil \(N-(2\text{-fluorophenyl})-\text{2-methoxy-N-[1-(2-phenylethyl)]piperidin-4-ylacetamide}\) 9838

(64) 4-methoxy butyryl fentanyl \(N-(4\text{-methoxyphenyl})-\text{N}-(\text{1-phenethylpiperidin-4-yl})\text{butyramide mono hydrochloride}\)

(65) Para-fluorobutyryl fentanyl \(N-(4\text{-fluorophenyl})-\text{N-[1-(2-phenylethyl)-4-piperidinyl]}\text{-butanamide mono hydrochloride}\)

(66) Acetyl norfentanyl \(N\text{-phenyl-N-4-piperidinyl-acetamide mono hydrochloride}\)

(67) AH-7921 3,4-dichloro-N-\{[1dimethylamino)cyclohexyl methyl]benzamide\)

(68) W-18 1-(4-nitrophenylethyl)piperidylidene-2-(4-chlorophenyl)sulfonamide

(69) W-15 1-phenylethylpiperidylidene-2-(4-chlorophenyl)sulfonamide

(70) MT-45 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine
(71) U-47700 trans-3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide
(72) Acyl fentanyl N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide------------------- 9811
(73) 4-Fluoroisobutyryl fentanyl N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide------- 9824
(74) Tetrahydrofuranyl fentanyl N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide------ 9843

(c) Opium derivatives: [Narcotic Drugs] Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Acetorphine ---------------------------------- 9319*
(2) Acetyldihydrocodeine ------------------------ 9051*
(3) Benzylmorphine ----------------------------- 9052*
(4) Codeline methylbromide ---------------------- 9070*
(5) Codeline-N-Oxide --------------------------- 9053*
(6) Cyprinomorphine ----------------------------- 9054*
(7) Desomorphine ------------------------------- 9055*
(8) Dihydrromorphine ---------------------------- 9145*
(9) Droteranol ------------------------------- 9335*
(10) Etorphine (except hydrochloride salt) ------- 9056*
(11) Heroin ---------------------------------- 9200*
(12) Hydromorphinol ---------------------------- 9301*
(13) Methyldeosorhine --------------------------- 9302*
(14) Methyldihydmorphine ----------------------- 9304*
(15) Morphine methylbromide --------------------- 9305*
(16) Morphine methylsulfonate ------------------- 9306*
(17) Morphine-N-Oxide -------------------------- 9307*
(18) Myrophanine ------------------------------- 9308*
(19) Nicocodeline ------------------------------- 9309*
(20) Nicomorphine ------------------------------- 9312*
(21) Nornorphine ------------------------------- 9313*
(22) Pholcodine ------------------------------- 9314*
(23) Thebapon -------------------------------- 9315*
(24) Mitragynine -------------------------------- 9316*
(25) 7-Hydroxymitragynine ----------------------- 9317*

(d) Hallucinogenic substances: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of the following hallucinogenic substance, or which contains any of its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation (for purposes of this paragraph only, the term "isomer" includes the optical, position and geometric isomers):

(1) alpha-ethyltryptamine ------------------------- 7249-(12-93)
Some trade or other names: etryptamine; Monoase;
alphamethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; alpha-ET; and AET.

(2) 4-bromo-2,5-dimethoxy-amphetamine ------------------ 7391*
Some trade or other names: 4-bromo-2,5-dimethoxy-
alpha-methylphenethylamine; 4-bromo-2,5-DMA.

(3) 4-bromo-2,5-dimethoxyphenethylamine ------------------ 7392-(8-95)
Some trade or other names: 2-(4-bromo-2,5-dimethoxyphenyl)-1
aminoethane; alpha-desmethyl DOB; 2C-B, Nexus.

(4) 2,5-dimethoxyamphetamine ------------------------ 7396*
Some trade or other names: 2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA.

(5) 2,5-dimethoxy-4-ethylamphetamin e ---------------------- 7399-(3-88)
Some trade or other names: DOET.

(6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine ----------- 7348-(1-05)
Some trade or other names: 2C-T-7.

(7) 4-methoxyamphetamine ------------------------------- 7411*
Some trade or other names: 4-methoxy-alpha-methylphenethylamine; paramethoxyamphetamine; PMA.

(8) 5-methoxy-3,4-methylenedioxy-amphetamine ----------- 7401*
(9) 4-methyl-2,5-dimethoxyamphetamine ------------------ 7395*
Some trade and other names: 4-methyl-2,5-dimethoxyalphaethylphenethylamine; "DOM"; and "STP".

(10) 3,4-methylenedioxy amphetamine ---------------------- 7400*

(11) 3,4-methylenedioxyamphetamine --------------------- 7405-(10-85)
Some trade or other names: MDMA.

(12) 3,4-methylenedioxy-N-ethylamphetamine -------------- 7404-(6-90)
Some trade or other names: N- ethyl-alpha-methyl-3,4 (methylene dioxy) phenethylamine, N-ethyl MDA; MDE;
MDEA.

(13) N-hydroxy-3,4-methylenedioxyamphetamine ------------ 7402-(6-90)
Some trade or other names: N-hydroxy-alpha-methyl-3,4 (methylene dioxy) phenethylamine; N-hydroxy MDA

(14) 3,4,5-trimethoxy amphetamine ------------------------ 7390*

(15) 5-methoxy-n,n-dimethyltryptamine 5-MeO-DMT---------- 7431*(01-11)

(16) alpha-methyltryptamine ----------------------------- 7432-(7-05)
Some trade or other names: AMT

(17) Bufotenine ------------------------------------------ 7433*
Some trade and other names: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin;
5-hydroxy-N,N-dimethyltryptamine; mappine.

(18) Diethyltryptamine ---------------------------------- 7434*
Some trade or other names: N,N-Diethyltryptamine;
DET.

(19) Dimethyltryptamine ------------------------------- 7435*
Some trade or other names: DMT

(20) 5-methoxy-N,N-disopropyltryptamine ------------------ 7439-(7-05)
Some trade or other names: 5-MeO-DIPT.

(21) Ibogaine ------------------------------------------ 7260*
Some trade and other names: 7-Ethyl-6,6 beta; 7,8,9,
10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido
[1',2': 1,2] azepino [5,4-b] indole; Tabernanthene
iboga.

(22) Lysergic acid diethylamide ------------------------- 7315*

(23) Mescaline ----------------------------------------- 7381*

(24) Parahexyl ----------------------------------------- 7374-(7-83)
Some trade or other names: 3-hexyl-1-hydroxy-
7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo
[b,d] pyran; Synhexyl.

(25) Peyote -------------------------------------------- 7415*
Meaning all parts of the plant presently classified
botanically as Lophophora williamsii Lemaire, whether
growing or not; the seeds thereof; any extract from
any part of such plant; and every compound,
manufacture, salts, derivative, mixture or
preparation of such plant, its seeds or extracts.
(Interprets 21 USC 812 (c), Schedule I (c) (12)).

(26) N-ethyl-3-piperidyl benzilate ---------------------- 7482*
(27) N-methyl-3-piperidyl benzilate ................................. 7484*
(28) Psilocybin .......................................................... 7437*
(29) Psilocyn ............................................................ 7438*
(30) Ethylamine Analog of phencyclidine .......................... 7455*
   Some trade or other names:
   N-ethyl-1-phenylcyclohexylamine, 
   (phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl) 
   ethylamine; cyclohexamine; PCE.
(31) Pyrrolidine Analog of phencyclidine ......................... 7458*
   Some trade or other names: 1-(1-phenylcyclohexyl)- 
   pyrrolidine; PCPy; PHP
(32) Thiophene Analog of phencyclidine .......................... 7470*
   Some trade or other names: 1-[1-(2-thienyl) 
   cyclohexyl] Piperidine; 2-Thienyl analog of 
   phencyclidine; TCP; TCP.
(33) 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine ..................... 7473-(9-89) 
   Some other trade or other names: TCPy.
(34) N,N-Diallyl-5-Methoxytryptamine; Some trade or other names: 
      5-MeO DALT; 5-Methoxy-DALT.
(35) 2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl) 
      methyl]ethanamine; 25C-NBOMe
(36) 2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl) 
      methyl]ethanamine; 25I-NBOMe
(37) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine; 2C-EB----- 7509
(38) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine; 2C-D----- 7508
(39) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine; 2C-C----- 7519
(40) 2-(4-Todo-2,5-dimethoxyphenyl)ethanamine; 2C-I------- 7518
(41) 2-(4-Ethylthio)-2,5-dimethoxyphenyl|ethanamine;  
      2C-T-2------------------------------------------------- 7385
   2-(4-Isopropylthio)-2,5-dimethoxyphenyl|ethanamine;  
   2C-T-4-------------------------------------------------- 7532
(43) 2-(2,5-Dimethoxyphenyl)ethanamine; 2C-H------------- 7517
(44) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine; 2C-N------ 7521
(45) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine;  
      2C-P------------------------------------------------- 7524
(46) 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) 
      ethanamine; 25B-NBOMe
(47) 2-[[2-(4-Bromo-2,5-dimethoxyphenyl)ethyl]amino]methyl]- 
      phenol; 25B-NBOH
(48) 2-[[2-(4-Iodo-2,5-dimethoxyphenyl)ethyl]amino]methyl]- 
      phenol; 25I-NBOH
(49) 2-(4-Ethyl-2,5-dimethoxyphenyl)-N-(2-methoxyphenyl) 
      methyl]ethanamine; 25E-NBOMe
(50) 2-(2,5-Dimethoxyphenyl)-N-[2-methoxyphenyl] 
      methyl]ethanamine; 25H-NBOMe
(51) 2-[[2-(4-Chloro-2,5-dimethoxyphenyl)ethyl]amino]methyl]- 
      phenol; 25C-NBOH
(52) 2-[[2-(2,5-Dimethoxyphenyl)ethyl]amino]methyl]-phenol;  
      25H-NBOH

(e) **Depressants:** Unless specifically excepted or unless listed in another 
   schedule, any material, compound, mixture, or preparation which contains any 
   quantity of the following substances having a depressant effect on the central 
   nervous system, including its salts, isomers, and salts of isomers whenever 
   the existence of such salts, isomers, and salts of isomers is possible within the 
   specific chemical designation:

   (1) Phencyclidine
   (2) gamma-hydroxybutyric acid (some other names include
GHR; gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutyric acid; sodium oxybate; sodium oxybutyrate), and its known precursors and analogs -- 2010-(2-01)
(3) Mecloqualone ----------------------------------------------- 2572*
(4) Methaqualone --------------------------------------------- 2565*
(5) Etizolam

(f) Stimulants: (a) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:

(1) Cathinone --------------------------------------------------- 1235-(3-88)
(2) (±) CIS-4-Methylaminorex [±] CIS-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine] --------------- 1590-(6-90)
(3) Fenethylline ------------------------------------------------ 1503-(9-81)
(4) N-Benzylpiperazine------------------------------------------ 7493-(1-05)
Some trade or other names: BZF, 1-Benzylpiperazine
(5) N-ethylamphetamine ----------------------------------------- 1475-(6-82)
(6) N-[1-(1-benzyl-4-piperidyl)]-N-phenylpropamide (benzylfentanyl), its optical isomers, salts and salts of isomers ------------------------------- 9818-(2-86)
(7) N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropamide (thienylfentanyl), its optical isomers, salts and salts of isomers ------------------------------- 9834-(2-86)
(8) N, N, Dimethylamphetamine (some other names: N, N Alpha-trimethylbenzeneethanamine; N, N, Alpha-trimethylphenethylamine), its salts, optical isomers, and salts of optical isomers ------------------------------- 1480-(2-89)
(9) Methcathinone (some other names:
  2-Methylamine-Propophenone, alpha (methylamino)-Propophenone, 2 (methylamino)-1-phenylpropan-1-one, alpha-N-Methylaminopropophenone, monomethylpropiion, ephedrone, N-methylcathinone, methcathinone, AL-464, AL-422, AL-463 and UR-1431), its salts, optical isomers and salts of optical isomers ------------------------------- 1237-(12-93)
(10) Aminorex (some other names: aminophen, 2-amino-5-phenyl-2-oxazoline, or 4,5 dihydro-5-phenyl-2-oxazolamine, its salts, optical isomers, and salts of optical isomers ------------------------------- 1585-(12-93)
(11) Methyl-N-ethylcathinone (MEC)
(b) Any material, compound, mixture, or preparation, whether produced directly or indirectly from a substance of vegetable origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis, that contains any quantity of the following substances, or that contains any of the following substances' analogs, salts, isomers, and salts of isomers when the existence of the analogs, salts, isomers, and salts of isomers is possible within the specific chemical designation, with the following chemical structure is included in Schedule I:

(1) 4-Methylmethcathinone (Mephedrone) ------------------------ 1248-(3-11)
(2) Methylenedioxypropyrovalezone (MDPV) ---------------------- 1248-(3-11)
(3) 3,4-Methylenedioxy-N-methylcathinone (Methylene) 7540-(3-11)
(4) 4-Methoxymethcathinone ------------------------------------- 7540-(3-11)
(5) 3-Fluoromethcathinone -------------------------------------- 7540-(3-11)
(6) 4-Fluoromethcathinone or ---------------------------------- 7540-(3-11)
(7) 1-(1,3-benzodioxol-5-yl)-2-methylamino)butan-1-one (Butyline)
(8) Alpha-Pyrrolidinopentiophenone (Alpha-PVP)
(9) 4-methyl-N-ethylcathinone (4-MEC)
(10) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP)
(11) 2-(methylamino)-1-phenylpental-1-one (Pentedrone)

DRAFT 6/3/2019
(12) 1-(1,3-benzodioxol-5-yi)-2-(methylamino)pentan-1-one (Pentylone, MBDP)
(13) 4-fluoro-N-methylcathinone (4-FMC, Fledereone)
(14) 3-fluoro-N-methylcathinone (3-FMC)
(15) 1-(naphthalen-2-yl)-2-(pyrroolidin-1-yl)pentan-1-one (Naphyrone)
(16) Alpha-pyrroolidinobutiohexophene ([Alpha]-PBP) or
(17) A compound, unless listed in another schedule or a
legend drug, that is structurally derived from
2-Amino-phenyl-1-propanone by modification or by
substitution:
(A) In the phenyl ring to any extent with alkyl,
alkoxy, alkylenedioxy, haloalkyl or halide
substituents, whether or not further
substituted in the phenyl ring by one (1) or
more other univalent substituents;
(B) At the 3-position with an alkyl substituent; or
(C) At the nitrogen atom with alkyl or dialky1
groups, or by inclusion of the nitrogen atom in
a cyclic structure.
(18) N-Ethylpentylone, or 1-(1,3-benzodioxol-5-yi)-2-(ethylamino)-pentan-
1-one

Schedule II
(a) Schedule II shall consist of the drugs and other substances, by whatever
official name, common or usual name, chemical name, or brand name designated,
listed in this section. Each drug or substance has been assigned the Controlled
Substances Code Number set forth opposite it.

(b) Narcotic Drugs: Substances, vegetable origin or chemical synthesis.
Unless specifically excepted or unless listed in another schedule, any of the
following substances whether produced directly or indirectly by extraction from
substances of vegetable origin, or independently by means of chemical synthesis,
or by combination of extraction and chemical synthesis:

(1) Opium and opiate, and any salt, compound, derivative, or preparation
of opium or opiate, excluding apomorphine, dextrophan, nalbuphine,
naloxone, naloxone and naltrexone and their respective salts, but
including the following:
(1) Raw opium ----------------------------------------------- 9600*
(2) Opium extracts ------------------------------------------ 9610*
(3) Opium fluid extracts ------------------------------------ 9620*
(4) Powdered opium ----------------------------------------- 9639*
(5) Granulated opium ---------------------------------------- 9640*
(6) Tincture of opium ---------------------------------------- 9630*
(7) Codeine ----------------------------------------------------- 9050*
(8) Dihydroetorphine ---------------------------------------- 9334*
(9) Ethylmorphine --------------------------------------------- 9190*
(10) Etorphine hydrochloride ---------------------------------- 9059*
(11) Hydromorphone ------------------------------------------ 9150*
(12) Hydrocodeone ------------------------------------------- 9193*
(13) Metopon ----------------------------------------------- 9260*
(14) Morphine ----------------------------------------------- 9300*
(15) Oriphaine ----------------------------------------------- 9330*(9-07)
(16) Oxycodeone --------------------------------------------- 9143*
(17) Oxyinorphone -------------------------------------------- 9652*
(18) Thebain ----------------------------------------------- 9333*
(19) Tapentadol --------------------------------------------- 9780-(5-09)

(2) Any salt, compound, derivative, or preparation thereof which is
chemically equivalent or identical with any of the substances
referred to in paragraph (b) (1) of this section, except that these
substances shall not include the isoquinoline alkaloids of opium.*
(3) Opium poppy and poppy straw.*
(4) Coca leaves (904C) and any salt, compound, derivative, or preparation of coca leaves, (including cocaine (904I) and ecgonine (918G) and their salts, isomers, derivatives and salts of isomers and derivatives), and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, except that the substances shall not include decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine.*
(5) Concentrate or poppy straw (the crude extract of poppy straw in either liquid, solid or powder form which contains the phenanthrine alkaloids of the opium poppy), 9670.*

(c) **Opiates:** (Narcotic Drugs) Unless specifically excepted or unless in another schedule, any of the following opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designations:

(1) Alfentanil ------------------------------- 9737-(2-87)
(2) Alphaprodine ----------------------------- 9010*
(3) Anileridine ------------------------------ 9020*
(4) Bezitramide ------------------------------- 9800*
(5) Bulk Dextropropoxyphene {non-dosage forms} --------- 9273-(9-81)
(6) Carfentanil ------------------------------- 9743-(9-88)
(7) Dihydrocodeine -------------------------------- 9120*
(8) Diphenoxylate ----------------------------- 9170*
(9) Fentanyl ---------------------------------- 9801*
(10) Isomethadone -------------------------------- 9226*
(11) Levo-alphacetylmethadol (LAAM) ----------------- 9648-(12-93)
(12) Levomethorphan -------------------------- 9210*
(13) Levorphanol ------------------------------ 9220*
(14) Metazocine -------------------------------- 9240*
(15) Methadone -------------------------------- 9250*
(16) Methadone-Intermediate, 4-cyano-2- dimethylamino-4, 4-diphenyl butane ---------------- 9254*
(17) Moramide-Intermediate, 2-methyl-3- morpholinol-1, 1-diphenylpropane- carboxylic acid ---------------------------------- 9802*
(18) Pethidine (Meperidine) --------------------- 9230*
(19) Pethidine-Intermediate A, 4-cyano-1- methyl-4-phenylpiperidine ---------------- 9232*
(20) Pethidine-Intermediate B, ethyl-4- phenylpiperidine-4-carboxylate ----------------- 9233*
(21) Pethidine-Intermediate C, 1-methyl-4- phenylpiperidine-4-carboxylic acid -------------- 9234*
(22) Phenazocine ------------------------------- 9715*
(23) Piminodine -------------------------------- 9730*
(24) Racemethorphan ---------------------------- 9732*
(25) Racemorphan ------------------------------- 9733*
(26) Remifentanil ------------------------------- 9739-(11-96)
(27) Sufentanil -------------------------------- 9740-(9-81)

(d) **Stimulants:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system:

(1) Amphetamine, its salts, optical isomers, and salts of its optical isomers --------------------------- 1100*
(2) Methamphetamine, its salts, isomers, and salts
of its isomers -------------------------------------------------- 1105*
(3) Lisdexamfetamine ------------------------------------------ 1205*(7-07)
(4) Phenmetrazine and its salts ----------------------------- 1631*
(5) Methylphenidate ----------------------------------------- 1724*

(e) **Depressants:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Amobarbital --------------------------------------------- 2125*
(2) Glutethimide ------------------------------------------- 2550-(2-91)
(3) Pentobarbital ------------------------------------------- 2270*
(4) Phencyclidine ------------------------------------------- 7471*
(5) Secobarbital ------------------------------------------- 2315*

(f) **Hallucinogenic Substances:**

(1) Nabilone ------------------------------------------------- 7379-(11-87)
[Another name for nabilone: (+)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,9,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pran-9-one].

(2) Dronabinol in an oral solution in a drug product approved for marketing by the U.S. Food and Drug Administration; [(-)-delta-9-trans-tetrahydrocannabinol (delta-9-THC)].--------7365

(g) **Immediate Precursor:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances:

(1) Immediate precursor to Amphetamine and Methamphetamine:
   (i) Phenylacetone ------------------------------------------ 8501-(3-80)
   Some trade or other names: phenyl-2-propanone; P2P; benzyl methyl Ketone; methyl benzyl Ketone.

(2) Immediate precursor to Phencyclidine (PCP):
   (i) 1-phenylcyclohexylamine ----------------------------- 7460*
   (ii) 1-piperidinocyclohexanecarbonitrile (PCC) ------- 8603*

(3) Immediate precursor to Fentanyl:
   (i) 4-anilino-N-phenethylpiperidine (ANPP) ------------- 8333*(08-10)

**Schedule III**

(a) Schedule III shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.

(b) **Stimulants:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under Section 308.32,
and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances------------------------ 1405*

(2) Benzphetamine --------------------------------- 1228*
(3) Chlorphentermine ----------------------------- 1645*
(4) Clortermine --------------------------------- 1647*
(5) Phendimetrazine ----------------------------- 1615*

(c) **Depressants:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:

(1) Any compound, mixture, or preparation containing:
   (i) Amobarbital ---------------------------------- 2126*
   (ii) Secobarbital --------------------------------- 2316*
   (iii) Pentobarbital ------------------------------- 2271*
   (iv) Embutramide ---------------------------------- 2020*(9-06)
   or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule.

(2) Any suppository dosage form containing:
   (i) Amobarbital ---------------------------------- 2126*
   (ii) Secobarbital --------------------------------- 2316*
   (iii) Pentobarbital ------------------------------- 2271*
   or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository.

(3) Any substance which contains any quantity of a derivative of barbituric acid or any salt thereof---- 2100*

(4) Chlorhexadol ------------------------------- 2510*

(5) Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the Federal Food, Drug, and Cosmetic Act------------------------ 2012-(2-01)

(6) Ketamine. its salts, isomers, and salts of isomers--- 7285-(7-99)
   Some other names for Ketamine: (+)-2-(2-Chlorophenyl)-2-(Methylamino)-Cyclohexanone.

(7) Lysergic acid ---------------------------------- 7300*

(8) Lysergic acid amide ---------------------------- 7310*

(9) Methyprylon ---------------------------------- 2575*

(10) Fondiethylmethane ---------------------------- 2600*

(11) Sulfonemethylthane ---------------------------- 2605*

(12) Sulfonmethane -------------------------------- 2610*

(13) Tiletamine and zolazepam or any salt thereof --- 7295-(3-88)
   Some trade or another name for a tiletamine-zolazepam combination product: Telazol.
   Some trade or other names for tiletamine:
   -2(ethylamino)-2-(2-thienyl)-cyclohexanone.
   Some trade or other names for zolazepam:
   -4(2-fluorophenyl)-6,8-dihydro-1,3,8,-trimethylpyrazolo-(3,4-e) [1,4]-diazepin-7
   (1-H)-one. flupyrazapon.

(14) Perampanel ----------------------------------- 2261-(11-13)

(d) **Nalorphine** ---------------------------------- 9400*
(e) **Narcotic drugs**: Unless specifically excepted or unless listed in another schedule:

(1) any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

(i) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium ---------------------------------- 9803*

(ii) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts ----------------------------- 9804*

(iii) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts ----------------------------- 9807*

(iv) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts ----------------------------- 9808*

(v) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts ----------------------------- 9809*

(vi) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts ----------------------------- 9810*

(2) Any material, compound, mixture, or preparation containing any of the following narcotic drugs or their salts, as set forth below:

(i) Buprenorphine ------------------------------- 9064-(6-85)

(10-02 Transfer)

(ii) Reserved

(f) **Anabolic Steroids**: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts of isomers is possible within the specific chemical designation: Items 1–28 -------------------------- 4000-(9-91)

(1) Boldenone;
(2) Boldione;(01-10)
(3) Chlorotestosterone (4-chlorotestosterone);
(4) Clostebol;
(5) Dehydrochlormethyltestosterone;
(6) Dihydrotestosterone (4-dihydrotestosterone);
(7) Dihydrotestosterone (4-dihydrotestosterone);
(8) Drostanolone;
(9) Ethylestrenol;
(10) Fluoxymesterone;
(11) Formebulone (formebolone);
(12) Mesterolone;
(13) Methandienone, Methandrostenolone;
(14) Methandranone;
(15) Methandroil;
(16) Methenolone;
(17) Methyltestosterone;
(18) Mibolerone;
(19) Nandrolone;
(20) 19-Nor-4,9(10)-Androstanedione (01-10)
(21) Norethandrolone;
(22) Oxandrolone;
(23) Oxymesterone;
(24) Oxymetholone;
(25) Stanolone;
(26) Stanozolol;
(27) Testolactone;
(28) Testosterone;
(29) Trenbolone
(30) Prostanolone---------------------------------------------------------------{8-12}
(31) Mesterone---------------------------------------------------------------{8-12};
and
(32) Any salt, ester, or isomer of a drug or

substance described or list in this paragraph,

if that salt, ester, or isomer promotes muscle
growth.

(1) Exempt anabolic steroid products: Compounds,
mixtures, or preparations that contain an anabolic
steroid that have been exempted by the Director:

<table>
<thead>
<tr>
<th>Product Description</th>
<th>NDC Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andro-Estro 90-4------------------------------------------</td>
<td>0536-1605</td>
</tr>
<tr>
<td>Androyn L.A.---------------------------------------------</td>
<td>0456-1005</td>
</tr>
<tr>
<td>Component E-H in Process Pellets-------------------------</td>
<td>Ivy Labs Inc.</td>
</tr>
<tr>
<td>Component E-H in Process Granulation---------------------</td>
<td>Ivy Labs Inc.</td>
</tr>
<tr>
<td>Component TE-S in process Granulation---------------------</td>
<td>Ivy Labs Inc.</td>
</tr>
<tr>
<td>Component TE-S in process Pellets-------------------------</td>
<td>Ivy Labs Inc.</td>
</tr>
<tr>
<td>depANDROGYN---------------------------------------------</td>
<td>0456-1020</td>
</tr>
<tr>
<td>Depo-Testadiol-------------------------------------------</td>
<td>0009-0253</td>
</tr>
<tr>
<td>DEPO-T.E.----------------------------------------------</td>
<td>52765-257</td>
</tr>
<tr>
<td>depTESTROGEN-------------------------------------------</td>
<td>51698-257</td>
</tr>
<tr>
<td>Duomone-------------------------------------------------</td>
<td>52047-360</td>
</tr>
<tr>
<td>DUO-SPAN II--------------------------------------------</td>
<td>0684-0102</td>
</tr>
<tr>
<td>DURATESTRIN--------------------------------------------</td>
<td>43797-016</td>
</tr>
<tr>
<td>Essian-------------------------------------------------</td>
<td>Pharmaceutics</td>
</tr>
<tr>
<td>Essian H.S.---------------------------------------------</td>
<td>Pharmaceutics</td>
</tr>
</tbody>
</table>
| Esterified Estrogens & Methyltestosterone, USP
  (0.625 mg/1.25mg)---------------------------------------| Interpharm |
| Esterified Estrogens & Methyltestosterone, USP
  (1.25mg/2.5mg)-----------------------------------------| Interpharm |
| Esterified Estrogens & Methyltestosterone
  (0.625mg/1.25mg) Tablet---------------------------------| ANDApharm |
| Esterified Estrogens & Methyltestosterone
  (1.25mg/2.5mg) Tablet----------------------------------| ANDApharm |
| Estratest------------------------------------------------| 0032-1026 |
| Estratest HS-------------------------------------------| 0032-1023 |
| Menogen-------------------------------------------------| 59243-570 |
| Menogen HS---------------------------------------------| 59243-560 |
| Methyltestosterone & Esterified Estrogens
  (2.5mg/1.25Mg)----------------------------------------| Lannett Co |
| Methyltestosterone & Esterified Estrogens (Half

DRAFT 6/3/2019
<table>
<thead>
<tr>
<th>Strength</th>
<th>(1.25mg/0.625mg)</th>
<th>Lanett Co</th>
</tr>
</thead>
<tbody>
<tr>
<td>(26) PAN Estra TEST</td>
<td></td>
<td>0525-0175</td>
</tr>
<tr>
<td>(27) Premarin with Methyltestosterone</td>
<td></td>
<td>0046-0879</td>
</tr>
<tr>
<td>(28) Premarin with Methyltestosterone</td>
<td></td>
<td>0046-0878</td>
</tr>
<tr>
<td>(29) Synest D.S.</td>
<td></td>
<td>66576-231</td>
</tr>
<tr>
<td>(30) Synest H.S.</td>
<td></td>
<td>66576-230</td>
</tr>
<tr>
<td>(31) Synovex H in process bulk pellets</td>
<td></td>
<td>Syntex Animal</td>
</tr>
<tr>
<td>(32) Synovex H in process granulation</td>
<td></td>
<td>Syntex Animal</td>
</tr>
<tr>
<td>(33) Synovex Plus in process granulation</td>
<td></td>
<td>Fort Dodge</td>
</tr>
<tr>
<td>(34) Synovex Plus in process bulk pellets</td>
<td></td>
<td>Fort Dodge</td>
</tr>
<tr>
<td>(35) TEST-ESTRO Cycionates</td>
<td></td>
<td>0536-9470</td>
</tr>
<tr>
<td>(36) Testoderm with Adhesive 4mg/d</td>
<td></td>
<td>Alza Corp.</td>
</tr>
<tr>
<td>(37) Testoderm 4mg/d</td>
<td></td>
<td>17314-4608</td>
</tr>
<tr>
<td>(38) Testoderm 6mg/d</td>
<td></td>
<td>17314-4609</td>
</tr>
<tr>
<td>(39) Testoderm with Adhesive 6mg/d</td>
<td></td>
<td>17314-2836</td>
</tr>
<tr>
<td>(40) Testoderm in process film</td>
<td></td>
<td>Alza Corp.</td>
</tr>
<tr>
<td>(41) Testoderm with Adhesive in process film</td>
<td></td>
<td>Alza Corp.</td>
</tr>
<tr>
<td>(42) Testosterone Cyponate/Estradiol Cyponate injection</td>
<td></td>
<td>54274-530</td>
</tr>
<tr>
<td>(43) Testosterone Cyponate/Estradiol Cyponate injection</td>
<td></td>
<td>0182-3069</td>
</tr>
<tr>
<td>(44) Testosterone Cyp 50 Estradiol Cyp 2</td>
<td></td>
<td>0814-7737</td>
</tr>
<tr>
<td>(45) Testosterone Cyponate/Estradiol Cyponate injection</td>
<td></td>
<td>0364-6611</td>
</tr>
<tr>
<td>(46) Testosterone Cyponate/Estradiol Cyponate injection</td>
<td></td>
<td>0402-0257</td>
</tr>
<tr>
<td>(47) Testosterone Enanthate/Estradiol Valerate injection</td>
<td></td>
<td>0182-3073</td>
</tr>
<tr>
<td>(48) Testosterone Enanthate/Estradiol Valerate injection</td>
<td></td>
<td>0364-6618</td>
</tr>
<tr>
<td>(49) Testosterone Enanthate/Estradiol Valerate injection</td>
<td></td>
<td>0402-0360</td>
</tr>
<tr>
<td>(50) Testosterone Ophthalmic Solution</td>
<td></td>
<td>Allergan</td>
</tr>
<tr>
<td>(51) Tilapia Sex Reversal Feed (investigational)</td>
<td></td>
<td>Ranger, Inc.</td>
</tr>
</tbody>
</table>

(2) Veterinary Anabolic Steroid Implant Products:
Anabolic steroid products expressly intended for administration through implants in cattle or other nonhuman species exempted by the Director.

<table>
<thead>
<tr>
<th>Component</th>
<th>DIN/NCX</th>
<th>DIN/NCX</th>
</tr>
</thead>
<tbody>
<tr>
<td>E-H</td>
<td>021641-002</td>
<td></td>
</tr>
<tr>
<td>E-H</td>
<td>01968327</td>
<td></td>
</tr>
<tr>
<td>TE-S</td>
<td>01968304</td>
<td></td>
</tr>
<tr>
<td>T-H</td>
<td>0211641-006</td>
<td></td>
</tr>
<tr>
<td>T-S</td>
<td>0211641-005</td>
<td></td>
</tr>
<tr>
<td>F-TO</td>
<td>00093351</td>
<td></td>
</tr>
<tr>
<td>Finaplix-H</td>
<td>12799-807-10</td>
<td></td>
</tr>
<tr>
<td>Finaplix-S</td>
<td>12799-807-07</td>
<td></td>
</tr>
<tr>
<td>Heifer-old</td>
<td></td>
<td>Boehringer</td>
</tr>
<tr>
<td>Heifer-old</td>
<td></td>
<td>Ingelheim</td>
</tr>
<tr>
<td>Heifer-old</td>
<td></td>
<td>Ivy Lab.</td>
</tr>
<tr>
<td>Implus-H</td>
<td>0009-0434-01</td>
<td></td>
</tr>
<tr>
<td>Implus-H</td>
<td>06-0434-01</td>
<td></td>
</tr>
<tr>
<td>01968327</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Masculinizing Feed for Fish (Investigational)</td>
<td></td>
<td>Rangen, Inc.</td>
</tr>
<tr>
<td>Revalor-G</td>
<td>12799-811</td>
<td></td>
</tr>
<tr>
<td>Revalor-H</td>
<td>12799-810</td>
<td></td>
</tr>
<tr>
<td>Revalor-S</td>
<td>12799-809</td>
<td></td>
</tr>
<tr>
<td>Synovex H</td>
<td>0856-3901</td>
<td></td>
</tr>
<tr>
<td>Synovex H</td>
<td></td>
<td>Syntex</td>
</tr>
</tbody>
</table>
If veterinary products that are granted exempted status are subsequently distributed with the intent that they be used in humans, the distribution would be subject to the criminal sanctions of the CSA despite the drugs’ exempted status.

(g) **Hallucinogenic substances:**

(1) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration approved drug product ----------------------------- 7369-(11-87)

[Some other names for dronabinol:

(6α R-trans)-6α,7,8, 10α-tetrahydro-6, 6,
9-trimethyl-3-pentyl-6H-dibenzo [b,d]
phyran-1-ol, or (-)-delta 9-(trans)-
tetrahydrocannabinol]

**Schedule IV**

(a) Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.

(b) **Narcotic drugs:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

(1) Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.----------------------------- 9167*

(2) Dextro propanoxyphene (alpha-(+)-4-dimethylamino-
1,2-diphenyl-3-methyl-2-propionoxybutane) ------- 9278-(11-87)

(c) **Depressants:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Alprazolam ------------------------------- 2882-(6-82)
(2) Barbital ------------------------------- 2145*
(3) Bromazepam ------------------------------ 2748-(1-85)
(4) Camazepam ------------------------------ 2749-(1-85)
(5) Chloral betaine -------------------------- 2460* 
(6) Chloral hydrate -------------------------- 2465* 
(7) Chlordiazepoxide ------------------------ 2744* 
(8) Clopazam ------------------------------- 2751-(1-85)
(9) Clozapate ------------------------------- 2737* 
(10) Clorazepate ----------------------------- 2768* 
(11) Clothiazepam --------------------------- 2752-(1-85)
(12) Cloxazolam ----------------------------- 2753-(1-85)
(13) Delorazepam ---------------------------- 2754-(1-85)
(14) Diazipem ------------------------------- 2765* 
(15) Dichloralphenazone --------------------- 2467-(10-02)
(16) Estazolam ----------------------------- 2756-(1-85)
(17) Ethchlorvynol --------------------------- 2540* 
(18) Ethinamate ----------------------------- 2545* 
(19) Ethyl loflazepate ----------------------- 2758-(1-85)
(20) Fludiazepam 2759-(1-85)
(21) Flunitrazepam 2763-(1-85)
(22) Flurazepam 2767*
(23) Fospropofol 2138-(11-09)
(24) Halazepam 2762-(6-82)
(25) Haloxazolam 2771-(1-85)
(26) Ketazolam 2772-(1-85)
(27) Loprazolam 2773-(1-85)
(28) Lorazepam 2885*
(29) Lormetazepam 2774-(1-85)
(30) Mebutamate 2800*
(31) Medazepam 2836-(1-85)
(32) Meprobamate 2820*
(33) Methohexitol 2264*
(34) Methylphenobarbital (mephenobarbital) 2250*
(35) Midazolam 2884-(1-85)
(36) Nimetazepam 2837-(1-85)
(37) Nitrazebap 2834-(1-85)
(38) Nordiazepam 2838-(1-85)
(39) Oxazepam 2835*
(40) Oxazolam 2839*
(41) Paraldehyde 2585*
(42) Petrichloral 2591*
(43) Phenobarbital 2285*
(44) Pinazepam 2883-(1-85)
(45) Prazepam 2764*
(46) Quazepam 2881-(11-86)
(47) Temazepam 2925-(9-81)
(48) Tetrazebap 2886-(1-85)
(49) Triazolam 2887-(7-83)
(50) Zaleplon 2781-(9-99)
(51) Zolpidem 2783-(12-91)
(52) Zopiclone 2784-(01-06)
(53) Alfaxalone 2731-(02-14)
(54) Carisoprodol 8192-(4-97)
(55) Tramadol 9752-(8-07)
(56) Suvorexant 2223-(8-14)

(d) Fenfluramine: Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:
(1) Fenfluramine 1670*

(e) Stimulants: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) Cathine (+)-Norpeudephedrine 1230-(3-88)
(2) Diethylpropium 1610*
(3) Fenamfamin 1760-(3-88)
(4) Fenproporex 1575-(3-88)
(5) Mazindol 1605-(6-82)
(5) Mefenorex 1580-(3-88)
(6) Modafinil 1680-(1-99)
(7) Pemoline (including organometallic complexes
and chelates thereof) ------------------------------ 1530*
(9) Phentermine ------------------------------ 1640*
(10) Pipradrol ------------------------------ 1750-(9-81)
(11) Sibutramine ------------------------------ 1675-(2-98)
(12) SPA ((-)-1-dimethylamino-1,2-diphenylethane) ------ 1635-(9-81)
(13) Lorcaserin ------------------------------ 1625-(6-13)

(f) **Other substances:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts; isomers whether optical, position, or geometric, and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:

(1) Pentazocine -------------------------------- 9709-(4-79)
(2) Butorphanol -------------------------------- 9720-(4-97)
(3) Nalbuphine -------------------------------- (4-97)
(4) Kloxadoline -------------------------------- 9725

**Schedule V**

(a) Schedule V shall consist of the drugs and other substances by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section.

(b) **Narcotic Drugs:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs and their salts, as set forth below.

Reserved

(c) **Narcotic drugs containing nonnarcotic active medicinal ingredients.** Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs or salts thereof, which shall include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:

* (1) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams.
* (2) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams.
* (3) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams.
* (4) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit.
* (5) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams.
* (6) Not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.

(d) **Stimulants:** unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having stimulant effect on the central nervous system, including its salts, isomers and salts of isomers:

(1) Pyrvalerone ------------------------------ 1485-(3-88)
(2) Ephedrine: a -(Methylamino)ethyl]benzene-methanol; (10-95)
a-[(Methylamino) ethyl]benzyl alcohol;
2-methylamino-1-phenyl-1-propanol;
1-phenyl-1-hydroxy-2-methylaminopropane;
1-phenyl-2-methylaminopropanol;
a - hydroxy-b-methylaminopropylbenzene;

DRAFT 6/3/2019
a product which occurs in the Chinese herb
Ma Huang (Ephedra vulgaris, Ephedra sinica Stapf.,
Ephedra equisetina Bunge, Gnetaceae) in several
other Ephedra spp.

(3) Phenylpropanolamine ------------------------- (7-05)
(4) Pseudoephedrine ------------------------------ (7-05)

Pursuant to Ark. Code Ann. § 5-64-212 as amended in 2005, this Schedule V
classification shall NOT apply to any ephedrine, phenylpropanolamine, or
pseudoephedrine in liquid, liquid capsule, or liquid gel capsule form. However,
sales limits mandated by statute shall apply to all products with ephedrine,
phenylpropanolamine, or pseudoephedrine as a listed ingredient regardless of the
dosage form.

(e) **Depressants:** Unless specifically exempted or excluded or unless listed
in another schedule, any material, compound, mixture, or preparation which
contains any quantity of the following substances having a depressant effect on
the central nervous system, including its salts, isomers, and salts of isomers:

(1) Pregabalin [(S)-3-(aminomethyl)-
5-methylhexanoic acid]----------------------------- 2782-(01-06)
(2) Lacosamide ----------------------------- 2746-(05-09)
(3) Brivaracetam ----------------------------- 2710

(f) **Other substances:**

(1) A drug product in finished dosage formulation that
has been approved by the U.S. Food and Drug Admin-
istration that contains cannabidiol (2-[(1R-3-methyl
-6R-(1-methylethenyl)-2-cyclohexen-1-yl)-5-pentyl-1,
3-benzenediol) derived from cannabis and no more than
0.1 percent (w/w) residual tetrahydrocannabinols.

**Schedule VI**

(a) In addition to any substance placed in Schedule VI by the Director of the
Department of Health under § 5-64-214, any material, compound, mixture, or
preparation, whether produced directly or indirectly from a substance of
vegetable origin or independently by means of chemical synthesis, or by a
combination of extraction and chemical synthesis, that contains any quantity of
the following substances, or that contains any of their salts, isomers, and salts of
isomers when the existence of the salts, isomers, and salts of isomers is
possible within the specific chemical designation, is included in Schedule VI:

(1) Marijuana

(2) Tetrahydrocannabinols, unless the tetrahydrocannabinol is:
(A) Contained in hemp-derived cannabidiol;
(B) Not more than three-tenths of one percent (0.3%) of the hemp-
derived cannabidiol on a dry weight basis as verified by a
nationally accredited laboratory for quality, purity and
accuracy standards; and
(C) Not approved by the United States Food and Drug Administration
for marketing as a medication;

(3) A synthetic equivalent of:
(A) The substance contained in the Cannabis plant; or
(B) The substance contained in the resinous extracts of the
genus Cannabis;

(4) Salvia divinorum or Salvinorin A, which includes all parts of the
plant presently classified botanically as Salvia divinorum, whether
growing or not, the seeds of the plant, any extract from any part
of the plant, and every compound, manufacture, derivative, mixture,
or preparation of the plant, its seeds, or its extracts, including salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation:

(5) Synthetic substances, derivatives, or their isomers in the chemical structural classes described below in subdivisions (a)(5)(A)-(J) of this section and also specific unclassified substances in subdivision (a)(5)(K) of this section. Compounds of the structures described in this subdivision (a)(5), regardless of numerical designation of atomic positions, are included in this subdivision (a)(5). The synthetic substances, derivatives, or their isomers included in this subdivision (a)(5) are:

(A) (i) Tetrahydrocannabinols, including without limitation the following:
   (a) Delta-1 cis or trans tetrahydrocannabinol, and its optical isomers;
   (b) Delta-6 cis or trans tetrahydrocannabinol, and its optical isomers; and
   (c) Delta-3,4 cis or trans tetrahydrocannabinol, and its optical isomers.

   (ii) Dronabinol in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the United States Food and Drug Administration is not a tetrahydrocannabinol under this subdivision (a)(5)(A).

(B) Naphthoylindoles, or any compound structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholino)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation the following

   (i) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole;
   (ii) JWH-015, or 1-propyl-2-methyl-3-(1-naphthoyl)indole;
   (iii) JWH-016, or 1-propyl-3-(1-naphthoyl)indole;
   (iv) JWH-019, or 1-hexyl-3-(1-naphthoyl)indole;
   (v) JWH-073, or 1-butyl-3-(1-naphthoyl)indole;
   (vi) JWH-081, or 1-pentyl-3-(4-methoxy-1-naphthoyl)indole;
   (vii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole

   (viii) JWH-122, or 1-pentyl-3-(4-methyl-1-naphthoyl)indole;
   (ix) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole;
   (x) JWH-200, or 1-[2-(4-morpholino)ethyl]-3-(1-naphthoyl)indole;

   (xi) JWH-210, or 1-pentyl-3-(4-ethyl-1-naphthoyl)indole;
   (xii) JWH-398, or 1-pentyl-3-(4-chloro-1-naphthoyl)indole;
   (xiii) AM-2201, or 1-(5-fluoropentyl)-3-(1-naphthoyl)indole;
   (xiv) MAM2201, or (1-(5-fluoropentyl)-1H-indol-3-yl)-(4-methyl-1-naphthalenyl)methanone; and
   (xv) EAM2201, or (1-(5-fluoropentyl)-1H-indol-3-yl)-(4-ethyl-1-naphthalenyl)methanone;
   (xvi) THJ-2201, or (1-(5-fluoropentyl)-1H-indazol-3-yl)-(naphthalen-1-yl)methanone;

(C) Naphthylmethylinodoles, or any compound structurally derived from an H-indol-3-yl-(1-naphthyl) methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholino)ethyl group, whether or
not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation the following:

(i) JWH-175, or 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane; and

(ii) JWH-184, or 1-Pentyl-1H-3-yl-(4-methyl-1-naphthyl)methane;

(D) Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholiny1)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or 5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone;

(E) Naphthylmethylindenes, or any compound structurally derived from 1-(1-naphthylmethyl)indenone with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholiny1)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-176, or 2-1-[1-Naphthalenylmethylene]-1H-inden-3-yl]pentane;

(F) Phenylacetylindoles, or any compound structurally derived from 3-phenylacetilindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholiny1)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including without limitation the following:

(i) JWH-201, or 2-(4-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone;

(ii) JWH-203, or 1-Pentyl-3-(2-chlorophenylacetil)indole;

(iii) JWH-250, or 1-Pentyl-3-(2-methoxyphenylacetil)indole;

(iv) JWH-251, or 1-Pentyl-3-(2-methylphenylacetil)indole; and

(v) RCS-6, or 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetil)indole;

(G) Cyclohexylphenols, or any compound structurally derived from 2-(3-hydroxybenzilcyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholiny1)ethyl group, whether or not substituted in the cyclohexyl ring to any extent, including without limitation the following:

(i) CP 47,497 5-(1,1-dimethylheptyl)-2-{[1R,3S]-3-hydroxybenzilcyclohexyl)-phenol;

(ii) Cannabicycloheptanol or CP 47,497 C8 homologue, or 5-(1,1-dimethyloctyl)-2-{[1R,3S]-3-hydroxybenzilcyclohexyl)-phenol; and

(iii) CP 55,940, or 5-(1,1-dimethylheptyl)-2-{[1R,2R]-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)-phenol;

(H) Benzoylindoles, or any compound structurally derived from a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholiny1)ethyl group, whether or
not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including without limitation the following:

(i) AM-694, or 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole;
(ii) RCS-4, or 1-penty1-3-(4-methoxybenzoyl)indole;
(iii) WIN-46,098 or Pravadoline, or (4-Methoxyphenyl)-[2-methyl-1-{2-(4-morpholinyl)ethyl}]indol-3-yl)methane;
(iv) AM-2233, or 1-[(N-methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole; and
(v) RCS-4 (C4 homologue) or (4-methoxyphenyl)(1-buty1-1H-indol-3-yl)methane;

(I) Adamantoylindoles, or Adamantoylindazoles, including Adamantyl Carboxamide Indoles and Adamantyl Carboxamide Indazoles, or any compound structurally derived from 3-(1-adamantyl) indole, 3-(1-adamantyl) indazole, or 3-(2-adamantyl)indole by substitution at a nitrogen atom of the indole or indazole ring with alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole or indazole ring to any extent and whether or not substituted in the adamantyl ring to any extent, including without limitation the following:

(i) AM-1248, or 1-adamantyl-1-[(l-methylpiperidin-2-yl)methyl]indol-3-yl)methanone;
(ii) AB-001, or 1-adamantyl-1-penty1indol-3-yl)methanone;
(iii) JWH-018 adamantyl carboxamide, or 1-penty1-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indole-3-carboxamide, some other names: 2NE1;
(iv) AKB-48, or N-{(1-adamantyl)-penty1-1H-indazole-3-carboxamide;
(v) 5F-AKB-48, or N-{(3s,5s,7s)-adamantan-1-yl}-1-(5-fluoropentyl)-1H-indazole-3-carboxamide;
(vi) STS-135, or N-{(1-adamantyl)-1-(5-fluoropentyl)indole-3-carboxamide;

(J) Tetramethylcyclopropylcarbonylindoles or any compound structurally derived from 3-(2,2,3,3-tetramethylcyclopropylcarbonyl) indole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cyanoal kyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, [N-methylpiperidin-2-yl]methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent, including without limitation the following:

(i) UR-144, or (1-penty1indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone;
(ii) XLR-11, or [1-(5-fluoropentyl)-1H-indol-3-yl]-[2,2,3,3-tetramethylcyclopropyl)methanone;
(iii) A-796,260, or [1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone;
(iv) 5-Chloro-UR-144, or [(15-chloropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone;
(v) 5-Bromo-UR-144, or [1-(5-bromopentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone; and
(vi) A-834,735, or 1-(tetrahydropyran-4-ylmethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone;

(X) Unclassified Synthetic Cannabinoids, including without limitation the following:

(i) CP 50556-1 hydrochloride, or [(6S,6sR,9R,10aR)-9-hydroxy-6-methyl-3-(2R,5-phenylpentan-2-yl)oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl)acetate;
(ii) HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methylectan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
(iii) HU-211, or Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methylectan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol;
(iv) Dimethylheptylpyran or DMHP;
(v) WIN55,212-2, or 2,3-Dihydro-5-methyl-3-(4-morpholino)pyrrololo[1,2,3-de]-1,4-benzoxazin-6-yl-1-naphthalenylmethanone;
(vi) URB597, or [3-(3-carbamoylphenyl)phenyl] N-cyclohexylcarbamate;
(vii) URB754, or 6-methyl-2-{(4-methylphenyl)amino}-1-benzoxazin-4-one;
(viii) CB-13, or 1-naphthalenyl[4-(pentyloxy)-1-naphthenyl]-methanone;
(ix) URB602, or cyclohexyl N-(3-phenylphenyl)carbamate;
(x) PB-22, or quinolin-8-yl 1-(5-pentyl)-1H-indole-3-carboxylate;
(xi) 5F-PB-22, or quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate;
(xii) BB-22, or quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate;
(xiii) NNEI (MN-24), or N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide;
(xiv) 5F-NNEI, or 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-carboxamide;
(xv) 5-Fluoro-AMB, or n-[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine methyl ester;
(xvi) MMB-CHMICA, or methyl-(1-cyclohexylmethyl)-1H-indole-3-carboxyl-L-valinate;
(xvii) 5-Fluoro-ADB, or methyl 2-1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate;
(xviii) 5-Fluoro-MDMB-PICA, or methyl 2-1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate;
(xix) MDMB-CHMICA, or methyl 2-1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate;
(xx) FUB-AMB, or methyl 2-1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate;
(xxi) MDMB-FUBINACA, or methyl 2-1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate;
(xxii) AB-PINACA, or N-1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide;
(xxiii) AB-CHMINACA, or N-1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide;
(xxiv) MAB-CHMINACA, or N-1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide;
(xxv) AB-FUBINACA, or N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide;

(xxvi) ADB-PINACA, or N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide;

(xxvii) 5F-CUMYL-PINACA, or 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide.

(6) A synthetic substance, derivative, or its isomers with:
(A) Similar chemical structure to any substance described in subdivisions (a)(1)-(5) of this section; or
(B) Similar pharmacological effects to any substance described in subdivisions (a)(1)-(5) of this section.

(b) However, director shall not delete a controlled substance listed in this section from Schedule VI.

(c)(1) If notice has been given to the director that the United States Food and Drug Administration has designated, rescheduled, or descheduled a marijuana-derived substance under federal law and approved for marketing the marijuana-derived substance as a prescription medication, the director shall consider the designation, rescheduling, or descheduling of the marijuana-derived substance under this chapter.

*—Scheduled before April, 1979.
**—Schedule VI is revised to conform to Act 329 of 2013.